Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive
MSN MoneyCentral - ONCONASE is currently being evaluated in a confirmatory Phase IIIb clinical trial in unresectable malignant mesothelioma (UMM). Under the agreement terms, Alfacell grants exclusive marketing and distribution rights for ONCONASE to GENESIS
Facts About Asbestos
KGBT 4 - Asbestosis Lung Cancer Mesothelioma. Everyone who has ever breathed in asbestos fibers is not necessarily going to get one of these diseases. No one knows whether there is a safe level of exposure; however, the risk increases as the exposure
A soul-baring moment for Quartetto Gelato
Baltimore Sun - Steljes, 36, died Friday from malignant pleural mesothelioma, a rare form of cancer usually associated with asbestos exposure. Her funeral was held yesterday in Canada. Still, the group, including Steljes’ husband, Peter de Sotto, will travel to
Thank you, Thank you, Thank You
PRWeb - SF Jury Finds Chrysotile Asbestos Causes Rare Peritoneal Mesothelioma A jury awarded over $1.9 million to a 71 year old retired sheet metal worker who developed peritoneal mesothelioma from his prior on the job exposure to asbestos. - 2005-11
U-turn hope over asbestos compensation
Scotsman - About 1900 people die in the UK each year from mesothelioma, a cancer of the lining of the lungs or abdomen which is almost always caused by exposure to asbestos. Campaigner Des McNulty MSP said: “I’m very confident that the Executive is going to
Alfacell Corporation Files for U.S. Orphan Drug Designation for
MSN MoneyCentral - Food and Drug Administration (FDA) to obtain orphan designation for its lead drug candidate ONCONASE(R) (ranpirnase) for the treatment of patients with unresectable malignant mesothelioma (UMM). ONCONASE is currently being evaluated in a
Online Press Release
PRWeb - The recognized leader in online news and press release distribution service for small and medium-sized businesses and corporate communications. PRWeb pioneered Free Press Release Distribution and continues to set the standard for online news
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101)
MSN MoneyCentral - Intravenous belinostat (PXD101) is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination